Thyroid Nodule Evaluation
On this page
Direct answer
Most thyroid nodules are benign — the workup exists to find the 5–10% that are not — and it starts with a TSH, not a needle: a low TSH redirects the pathway to scintigraphy, where a functioning "hot" nodule is almost never cancerous. For the euthyroid majority, high-resolution ultrasound risk-stratifies (marked hypoechogenicity, microcalcifications, taller-than-wide shape, irregular margins, extrathyroidal extension, suspicious cervical nodes), and fine-needle aspiration targets nodules of about 1 cm and above with suspicious features. Cytology is reported in Bethesda categories carrying graduated malignancy risk — from about 0–3% for benign (II) up to 97–99% for malignant (VI) — and management follows the category, from surveillance to lobectomy to total thyroidectomy.
What you must remember
- Prevalence paradox: palpable nodules in roughly 5% of adults, ultrasound-detectable in up to half — but cancer in only 5–10% of nodules.
- TSH first: suppressed TSH → radioiodine scan; hot (functioning) nodules are rarely malignant; euthyroid or high TSH → ultrasound pathway.
- High-risk ultrasound features: marked hypoechogenicity, taller-than-wide configuration, spiculated/irregular margin, microcalcifications, extrathyroidal extension, abnormal cervical lymph nodes.
- FNA threshold: nodules ≥1 cm with suspicious features (sized by risk-tiered systems such as TI-RADS); spongiform and purely cystic nodules are not aspirated.
- Bethesda malignancy risks (approximate): I non-diagnostic (repeat), II benign 0–3%, III AUS/FLUS ~5–15%, IV follicular neoplasm ~15–30%, V suspicious ~60–75%, VI malignant 97–99%.
- Follicular (and Hürthle-cell) tumours cannot be classified malignant on FNA — capsular/vascular invasion requires histology; Bethesda IV leads to lobectomy for most.
- Papillary carcinoma is the commonest thyroid malignancy (Orphan-Annie eye nuclei, psammoma bodies, BRAF V600E association); medullary carcinoma needs calcitonin and RET testing.
- Clinical red flags: rapid growth, hoarseness, fixed hard nodule, age under 20 or over 60, male sex, neck irradiation history, family history of thyroid cancer or MEN2.
How the pathway works in practice
A 42-year-old woman notices a left thyroid lump; TSH is 2.1 mIU/L. Ultrasound shows a 1.6 cm solid, markedly hypoechoic nodule, taller than wide, with microcalcifications and a small level III node with microcystic change. This configuration is high-suspicion; FNA follows without scintigraphy (TSH normal). Cytology returns Bethesda VI — malignant — and, because the lesion exceeds 1 cm, total thyroidectomy with appropriate nodal management is standard, preceded by neck ultrasound mapping.
Contrast the intermediate pathway: a 1.8 cm isoechoic nodule with regular margins yields Bethesda III (atypia of undetermined significance). Options per current practice include repeat FNA after a interval, molecular testing where available, or diagnostic lobectomy — with the chosen route reflecting size, ultrasound suspicion and patient preference. In India, costly and unevenly available molecular testing tilts practice toward repeat FNA or lobectomy.
Below the 1 cm threshold, mildly suspicious nodules — an 0.8 cm lesion found on a carotid study, say — are observed with interval ultrasound rather than aspirated. Finally the family-history scenario: a nodule in a patient whose sibling had medullary carcinoma adds serum calcitonin and RET analysis to the workup — medullary cancer's management (and family screening) is entirely different from the follicular-derived cancers.
Where students slip
First, biopsy as reflex: FNA of every nodule regardless of size and ultrasound character — the correct first tests are TSH and ultrasound; scintigraphy enters only when TSH is low. Second, treating Bethesda IV as "cancer on cytology": follicular neoplasm is a histological dilemma, and the expected answer is lobectomy (or molecular testing where available), not radioiodine. Third, forgetting that pregnancy does not contraindicate FNA — suspicious nodules in pregnancy are aspirated, with surgery timed by trimester and risk. Fourth, ignoring the "hot nodule" logic: autonomously functioning nodules suppress TSH, show increased uptake, and are managed for thyrotoxicosis (definitive therapy or antithyroid drugs), essentially never for cancer. Finally, the paediatric caveat — nodules in children carry higher malignancy rates and deserve specialist referral rather than simple adult-pathway transfers.
Frequently asked questions
Why is TSH the first test in a thyroid nodule?
It routes the workup: a suppressed TSH calls for scintigraphy, and a hyperfunctioning (hot) nodule is almost always benign, making FNA unnecessary; normal or raised TSH proceeds down the ultrasound-guided pathway.
Which ultrasound features make a nodule suspicious?
Marked hypoechogenicity, taller-than-wide shape, irregular or spiculated margins, microcalcifications, extrathyroidal extension and suspicious cervical lymph nodes — formalised in risk-tiered systems such as TI-RADS.
What does a Bethesda category IV result mean?
A follicular (or Hürthle-cell) neoplasm, carrying roughly 15–30% malignancy risk that cytology cannot resolve, since capsular and vascular invasion — the diagnostic criteria — need histology; management is typically diagnostic lobectomy or molecular testing.
Is fine-needle aspiration safe during pregnancy?
Yes — FNA of a suspicious nodule is performed in pregnancy; surgery, if required, is safest in the second trimester, and deferred postpartum when risk permits.
Which nodule patients need calcitonin and RET testing?
Those with a family history of medullary thyroid carcinoma or MEN2, bilateral or multifocal disease with suspicious cytology, or clinical suspicion of medullary cancer — because MTC needs total thyroidectomy with central node dissection and family screening.